These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31043412)

  • 1. Delivering a STINGing Blow to Small Cell Lung Cancer via Synergistic Inhibition of DNA-Damage Response and Immune-Checkpoint Pathways.
    Hiatt JB; MacPherson D
    Cancer Discov; 2019 May; 9(5):584-586. PubMed ID: 31043412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected Synergy Reveals New Therapeutic Strategy in SCLC.
    Drapkin BJ; Farago AF
    Trends Pharmacol Sci; 2019 May; 40(5):295-297. PubMed ID: 30975441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
    Zhang H; Christensen CL; Dries R; Oser MG; Deng J; Diskin B; Li F; Pan Y; Zhang X; Yin Y; Papadopoulos E; Pyon V; Thakurdin C; Kwiatkowski N; Jani K; Rabin AR; Castro DM; Chen T; Silver H; Huang Q; Bulatovic M; Dowling CM; Sundberg B; Leggett A; Ranieri M; Han H; Li S; Yang A; Labbe KE; Almonte C; Sviderskiy VO; Quinn M; Donaghue J; Wang ES; Zhang T; He Z; Velcheti V; Hammerman PS; Freeman GJ; Bonneau R; Kaelin WG; Sutherland KD; Kersbergen A; Aguirre AJ; Yuan GC; Rothenberg E; Miller G; Gray NS; Wong KK
    Cancer Cell; 2020 Jan; 37(1):37-54.e9. PubMed ID: 31883968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung Cancer Subtypes Generate Unique Immune Responses.
    Busch SE; Hanke ML; Kargl J; Metz HE; MacPherson D; Houghton AM
    J Immunol; 2016 Dec; 197(11):4493-4503. PubMed ID: 27799309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
    Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
    Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.
    Meder L; König K; Fassunke J; Ozretić L; Wolf J; Merkelbach-Bruse S; Heukamp LC; Buettner R
    Exp Mol Pathol; 2015 Dec; 99(3):682-6. PubMed ID: 26546837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOTCH Your Usual Suspect: MYC Charged with Controlling Neuroendocrine Cell-Fate in Small Cell Lung Cancer.
    Ng J; Sutherland KD
    Cancer Cell; 2020 Jul; 38(1):17-20. PubMed ID: 32663464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?].
    Pujol JL; Roch B; Pujol CN; Goze C
    Bull Cancer; 2018 Oct; 105(10):955-966. PubMed ID: 30100047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
    Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
    Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
    Walls M; Baxi SM; Mehta PP; Liu KK; Zhu J; Estrella H; Li C; Zientek M; Zong Q; Smeal T; Yin MJ
    Clin Cancer Res; 2014 Feb; 20(3):631-43. PubMed ID: 24240111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CREB Pathway Suppresses Small Cell Lung Cancer.
    Xia Y; Zhan C; Feng M; Leblanc M; Ke E; Yeddula N; Verma IM
    Mol Cancer Res; 2018 May; 16(5):825-832. PubMed ID: 29523765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-cell lung cancer: an update on targeted therapies.
    Joshi M; Ayoola A; Belani CP
    Adv Exp Med Biol; 2013; 779():385-404. PubMed ID: 23288650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small cell lung cancer: Time to revisit DNA-damaging chemotherapy.
    Thomas A; Pommier Y
    Sci Transl Med; 2016 Jul; 8(346):346fs12. PubMed ID: 27384345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.
    Chae YK; Pan A; Davis AA; Mohindra N; Matsangou M; Villaflor V; Giles F
    Clin Lung Cancer; 2017 Mar; 18(2):132-140. PubMed ID: 27520630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
    Fujii K; Miyata Y; Takahashi I; Koizumi H; Saji H; Hoshikawa M; Takagi M; Nishimura T; Nakamura H
    Proteomics Clin Appl; 2018 Nov; 12(6):e1800015. PubMed ID: 29888431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.